A Study to Evaluate the Efficacy & Safety of Reslizumab in Patients With

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05398133` - Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma
Recruiting	`NCT04585997` - Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".	Phase 4
Recruiting	`NCT05985694` - AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma	Phase 2
Completed	`NCT03563521` - Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma
Completed	`NCT03469934` - Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma	Phase 2
Recruiting	`NCT04187976` - Eosinophils Endotypes in Chronic Airway Inflammatory Diseases
Recruiting	`NCT05813288` - A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)	Phase 3
Completed	`NCT03696914` - Intense Airway Eosinophilia in Asthma
Terminated	`NCT01290887` - Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma	Phase 3
Recruiting	`NCT04228588` - A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil	Phase 4
Recruiting	`NCT05748600` - A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma	Phase 3
Recruiting	`NCT05763121` - A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.	Phase 3
Completed	`NCT01508936` - Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma	Phase 3
Recruiting	`NCT04538937` - Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils
Completed	`NCT05002621` - Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
Completed	`NCT01270464` - A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma	Phase 3
Completed	`NCT04674137` - XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma	Phase 2
Recruiting	`NCT04671446` - Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma
Completed	`NCT04046939` - Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma	Phase 2
Completed	`NCT01287039` - A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma	Phase 3

NCT number	NCT01285323
Study type	Interventional
Source	Teva Branded Pharmaceutical Products R&D, Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	March 2011
Completion date	April 2014

A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms